Optimum Dose of pVGI.1(VEGF2) Gene Therapy for Severe Angina Pectoris Using Stiletto™ Injection Catheter

This study focuses on finding the best dose of a gene therapy called pVGI.1(VEGF2) for patients suffering from severe Angina Pectoris, a type of chest pain. The therapy is administered using an experimental injection catheter system known as Stiletto™. The goal is to understand how this treatment can benefit individuals dealing with this condition, potentially improving their quality of life and addressing the challenges associated with severe Angina Pectoris. During the study, participants receive the pVGI.1(VEGF2) gene therapy through the Stiletto™ catheter. The primary outcome measured is exercise tolerance, which helps evaluate the effectiveness of the treatment. This involves assessing the participants' ability to perform physical activities, providing insights into how well the therapy is working.